A Plus Biotechnology Co., Ltd.
A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of orthopedic and other medical devices. The company offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, biologics. It also provides technical support services and labor services. A Plus Biotechnology Co., Ltd. is based in New Taipei City, Ta… Read more
A Plus Biotechnology Co., Ltd. (6918) - Net Assets
Latest net assets as of September 2025: NT$1.25 Billion TWD
Based on the latest financial reports, A Plus Biotechnology Co., Ltd. (6918) has net assets worth NT$1.25 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.53 Billion) and total liabilities (NT$273.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.25 Billion |
| % of Total Assets | 82.08% |
| Annual Growth Rate | 2.88% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.84 |
A Plus Biotechnology Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how A Plus Biotechnology Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for A Plus Biotechnology Co., Ltd. (2021–2024)
The table below shows the annual net assets of A Plus Biotechnology Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$919.04 Million | +11.00% |
| 2023-12-31 | NT$827.94 Million | -5.68% |
| 2022-12-31 | NT$877.80 Million | +4.01% |
| 2021-12-31 | NT$843.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to A Plus Biotechnology Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 68.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$269.85 Million | 29.36% |
| Other Components | NT$649.19 Million | 70.64% |
| Total Equity | NT$919.04 Million | 100.00% |
A Plus Biotechnology Co., Ltd. Competitors by Market Cap
The table below lists competitors of A Plus Biotechnology Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bilendi
PA:ALBLD
|
$61.13 Million |
|
Altisource Portfolio Solutions SA
NASDAQ:ASPS
|
$61.15 Million |
|
Mobiltel Iletisim Hizmetleri Sanayi ve Ticaret AS
IS:MOBTL
|
$61.16 Million |
|
Taliworks Corporation Bhd
KLSE:8524
|
$61.16 Million |
|
Flat Capital AB Series B
ST:FLAT-B
|
$61.10 Million |
|
GENASYS INC. DL-00001
F:G66
|
$61.08 Million |
|
Insas Bhd
KLSE:3379
|
$61.08 Million |
|
AROBS TRANSILVANIA SOFTWARE SA
RO:AROBS
|
$61.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in A Plus Biotechnology Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 827,943,000 to 919,045,000, a change of 91,102,000 (11.0%).
- Net income of 151,056,000 contributed positively to equity growth.
- Dividend payments of 81,494,000 reduced retained earnings.
- Share repurchases of 16,250,000 reduced equity.
- New share issuances of 30,324,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$151.06 Million | +16.44% |
| Dividends Paid | NT$81.49 Million | -8.87% |
| Share Repurchases | NT$16.25 Million | -1.77% |
| Share Issuances | NT$30.32 Million | +3.3% |
| Other Changes | NT$7.47 Million | +0.81% |
| Total Change | NT$- | 11.00% |
Book Value vs Market Value Analysis
This analysis compares A Plus Biotechnology Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.08x to 2.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$27.70 | NT$85.40 | x |
| 2022-12-31 | NT$28.81 | NT$85.40 | x |
| 2023-12-31 | NT$27.43 | NT$85.40 | x |
| 2024-12-31 | NT$30.16 | NT$85.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently A Plus Biotechnology Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.44%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.63%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.28x
- Recent ROE (16.44%) is above the historical average (6.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 3.90% | 6.08% | 0.45x | 1.43x | NT$-51.45 Million |
| 2022 | 5.21% | 7.43% | 0.52x | 1.34x | NT$-42.08 Million |
| 2023 | -1.37% | -1.67% | 0.63x | 1.29x | NT$-94.10 Million |
| 2024 | 16.44% | 19.63% | 0.65x | 1.28x | NT$59.15 Million |
Industry Comparison
This section compares A Plus Biotechnology Co., Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,274,214,400
- Average return on equity (ROE) among peers: 6.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| A Plus Biotechnology Co., Ltd. (6918) | NT$1.25 Billion | 3.90% | 0.22x | $61.12 Million |
| Health & Life Co., Ltd. (1781) | $372.58 Million | -4.71% | 1.15x | $12.97 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.65 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.33 Billion | 1.93% | 1.30x | $38.32 Million |
| United Orthopedic (4129) | $1.77 Billion | 7.55% | 0.46x | $300.33 Million |
| Dynamic Medical Technologies (4138) | $1.76 Billion | 11.67% | 0.71x | $39.41 Million |
| Ok Biotech Co Ltd (4155) | $1.30 Billion | 9.66% | 0.71x | $44.61 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $30.42 Million |
| EPS Bio Technology Corp. (4183) | $309.15 Million | 10.25% | 0.77x | $4.27 Million |